All Stories

  1. Equivalent gain-of-function variants in KCNK3 and KCNK9 and their contribution to distinct TASK K2P channelopathies
  2. Book Review of “Textbook of Ion Channels” by Zheng J. and Trudeau M.C. (eds.), CRC Press, 2023
  3. Activation of TREK ‐1 and TREK ‐2 Two‐Pore Domain Potassium Channels by the K v 4 Channel Modulator...
  4. Genome Wide Association Analysis of Two Pore Domain Potassium Channel Gene Regions Reveals Multiple Pain-Associated Signals
  5. Equivalent Gain-of-Function Variants in KCNK3 and KCNK9 and their Contribution to Distinct TASK K2P Channelopathies
  6. The Concise Guide to PHARMACOLOGY 2025/26: Catalytic receptors
  7. The Concise Guide to PHARMACOLOGY 2025/26: Enzymes
  8. The Concise Guide to PHARMACOLOGY 2025/26: G protein‐coupled receptors
  9. The Concise Guide to PHARMACOLOGY 2025/26: Introduction and Other Protein Targets
  10. The Concise Guide to PHARMACOLOGY 2025/26: Ion channels
  11. The Concise Guide to PHARMACOLOGY 2025/26: Nuclear hormone receptors
  12. The Concise Guide to PHARMACOLOGY 2025/26: Transporters
  13. TASK-3, two-pore potassium channels, contribute to circadian rhythms in the electrical properties of the suprachiasmatic nucleus and play a role in driving stable behavioural photic entrainment
  14. The Contribution of Genetic Sequencing Information to the Identification and Functional Characterization of Two-Pore Domain Potassium (K2P) Channels as Viable Therapeutic Targets
  15. Screening for atrial fibrillation in care homes using pulse palpation and the AliveCor Kardia Mobile® device: a comparative cross-sectional pilot study
  16. The Concise Guide to PHARMACOLOGY 2023/24: Catalytic receptors
  17. The Concise Guide to PHARMACOLOGY 2023/24: Enzymes
  18. The Concise Guide to PHARMACOLOGY 2023/24: G protein-coupled receptors
  19. The Concise Guide to PHARMACOLOGY 2023/24: Introduction and Other Protein Targets
  20. The Concise Guide to PHARMACOLOGY 2023/24: Ion channels
  21. The Concise Guide to PHARMACOLOGY 2023/24: Nuclear hormone receptors
  22. The Concise Guide to PHARMACOLOGY 2023/24: Transporters
  23. A KCNB1 gain of function variant causes developmental delay and speech apraxia but not seizures
  24. HIV and Schistosoma Co-Exposure Leads to Exacerbated Pulmonary Endothelial Remodeling and Dysfunction Associated with Altered Cytokine Landscape
  25. Gain and loss of TASK3 channel function and its regulation by novel variation cause KCNK9 imprinting syndrome
  26. Aprepitant is a novel, selective activator of the K2P channel TRAAK
  27. THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Catalytic receptors
  28. THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Enzymes
  29. THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein‐coupled receptors
  30. THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Introduction and Other Protein Targets
  31. THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Ion channels
  32. THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Nuclear hormone receptors
  33. THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Transporters
  34. Block of TREK and TRESK K2P channels by lamotrigine and two derivatives sipatrigine and CEN-092
  35. The Prostacyclin Analogue, Treprostinil, Used in the Treatment of Pulmonary Arterial Hypertension, is a Potent Antagonist of TREK-1 and TREK-2 Potassium Channels
  36. Pharmacological Approaches to Studying Potassium Channels
  37. A “Target Class” Screen to Identify Activators of Two-Pore Domain Potassium (K2P) Channels
  38. Heterologous Expression of Ion Channels in Mammalian Cell Lines
  39. TRESK is a key regulator of nocturnal suprachiasmatic nucleus dynamics and light adaptive responses
  40. TASK-3 Two-Pore Potassium Channels drive neuronal excitability of the circadian clock and entrainment to challenging light environments
  41. Opportunistic screening for atrial fibrillation by clinical pharmacists in UK general practice during the influenza vaccination season: A cross-sectional feasibility study
  42. Two-Pore Domain Potassium Channels as Drug Targets: Anesthesia and Beyond
  43. Pharmacists detecting atrial fibrillation in general practice: a qualitative focus group study
  44. THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Catalytic receptors
  45. THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Enzymes
  46. THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G protein-coupled receptors
  47. THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Introduction and Other Protein Targets
  48. THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Ion channels
  49. THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Nuclear hormone receptors
  50. THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Transporters
  51. Pranlukast is a novel small molecule activator of the two-pore domain potassium channel TREK2
  52. Pharmacologically reversible, loss of function mutations in the TM2 and TM4 inner pore helices of TREK-1 K2P channels
  53. Effects of the ventilatory stimulant, doxapram on human TASK‐3 (KCNK9, K2P9.1) channels and TASK‐1 (KCNK3, K2P3.1) channels
  54. Infection in pulmonary vascular diseases: Would another consortium really be the way to go?
  55. Characterisation and regulation of wild type and mutant TASK-1 two pore domain potassium channels indicated in pulmonary arterial hypertension
  56. HIV transgene expression impairs K+ channel function in the pulmonary vasculature
  57. Activation of TREK currents by riluzole in three subgroups of cultured mouse nodose ganglion neurons
  58. Pharmacists detecting atrial fibrillation (PDAF) in primary care during the influenza vaccination season: a multisite, cross-sectional screening protocol
  59. GI-530159, a novel, selective, mechanosensitive two-pore-domain potassium (K2P ) channel opener, reduces rat dorsal root ganglion neuron excitability
  60. TASK-1 (KCNK3) channels in the lung: from cell biology to clinical implications
  61. Terbinafine is a novel and selective activator of the two-pore domain potassium channel TASK3
  62. Enhanced inflammatory cell profiles in schistosomiasis-induced pulmonary vascular remodeling
  63. Aristolochic acid, a plant extract used in the treatment of pain and linked to Balkan endemic nephropathy, is a regulator of K2P channels
  64. Two-pore domain potassium channels: potential therapeutic targets for the treatment of pain
  65. Influence of the N Terminus on the Biophysical Properties and Pharmacology of TREK1 Potassium Channels
  66. Enhancement of Current through Trek1 Two Pore Domain Channels by Flufenamic Acid
  67. Recovery of Current through Mutated TASK3 Potassium Channels Underlying Birk Barel Syndrome
  68. Enhancement of TWIK-related Acid-sensitive Potassium Channel 3 (TASK3) Two-pore Domain Potassium Channel Activity by Tumor Necrosis Factor  
  69. GuideToPharmacology.org - an update
  70. Guide to Receptors and Channels (GRAC), 5th edition
  71. Trafficking of Neuronal Two Pore Domain Potassium Channels
  72. SYMPOSIUM REVIEW: Gating of two pore domain potassium channels
  73. Ion channels as novel therapeutic targets in the treatment of pain
  74. Dominant Negative Effects of a Non-conducting TREK1 Splice Variant Expressed in Brain
  75. Guide to Receptors and Channels (GRAC), 4th edition
  76. The M1P1 Loop of TASK3 K2P Channels Apposes the Selectivity Filter and Influences Channel Function
  77. Guide to Receptors and Channels (GRAC), 3rd edition
  78. Identification of a region in the TASK3 two pore domain potassium channel that is critical for its blockade by methanandamide
  79. TASK-3 Two-Pore Domain Potassium Channels Enable Sustained High-Frequency Firing in Cerebellar Granule Neurons
  80. Gαq-Mediated Regulation of TASK3 Two-Pore Domain Potassium Channels: The Role of Protein Kinase C
  81. Guide to Receptors and Channels, 2nd edition (2007 Revision)
  82. Neuronal two-pore-domain potassium channels and their regulation by G protein-coupled receptors
  83. Zinc and copper: Pharmacological probes and endogenous modulators of neuronal excitability
  84. Guide to Receptors and Channels, 2nd edition
  85. The in Vivo Contributions of TASK-1-Containing Channels to the Actions of Inhalation Anesthetics, the α2 Adrenergic Sedative Dexmedetomidine, and Cannabinoid Agonists
  86. Modifying the Subunit Composition of TASK Channels Alters the Modulation of a Leak Conductance in Cerebellar Granule Neurons
  87. Guide to Receptors and Channels, 1st Edition (2005 revision)
  88. Inhibition of the human two-pore domain potassium channel, TREK-1, by fluoxetine and its metabolite norfluoxetine
  89. Selective block of the human 2-P domain potassium channel, TASK-3, and the native leak potassium current, IKSO, by zinc
  90. Two-Pore-Domain K+ Channels Are a Novel Target for the Anesthetic Gases Xenon, Nitrous Oxide, and Cyclopropane
  91. Neuronal ion channels and their sensitivity to extremely low frequency weak electric field effects
  92. What are the roles of the many different types of potassium channel expressed in cerebellar granule cells?
  93. What are the roles of the many different types of potassium channel expressed in cerebellar granule cells?
  94. Background potassium channels move into focus
  95. Pharmacological characterization of a non-inactivating outward current observed in mouse cerebellar Purkinje neurones
  96. Inhibition of the potassium current IKSO, in cerebellar granule cells, by the inhibitors of MEK1 activation, PD 98059 and U 0126
  97. MAMMALIAN TWO-PORE DOMAIN POTASSIUM CHANNELS
  98. TiPS nomenclature supplement 2001
  99. The role of Ca2+stores in the muscarinic inhibition of the K+currentIK(SO)in neonatal rat cerebellar granule cells
  100. Purinergic and muscarinic receptor activation activates a common calcium entry pathway in rat neocortical neurons and glial cells
  101. A functional role for the two-pore domain potassium channel TASK-1 in cerebellar granule neurons
  102. A functional role for the two-pore domain potassium channel TASK-1 in cerebellar granule neurons
  103. Inhibition of delayed rectifier K+conductance in cultured rat cerebellar granule neurons by activation of calcium-permeable AMPA receptors
  104. Inhibition of neuronal KV potassium currents by the antidepressant drug, fluoxetine
  105. Inhibition by inorganic ions of a sustained calcium signal evoked by activation of mGlu5 receptors in rat cortical neurons and glia
  106. Activation of group I metabotropic glutamate receptors elicits pH changes in cultured rat cortical glia and neurons
  107. Characterization of the hyperpolarization-activated chloride current in dissociated rat sympathetic neurons
  108. Voltage-activated potassium channels in mammalian neurons and their block by novel pharmacological agents
  109. Ion Channels: Molecules in Action. Edited by D. J.Aidleyand P. R.Stanfield. Pp. 340. Cambridge University Press, 1996. £17.95 paperback, ISBN 0521 49882 1. £50.00 hardback, ISBN 0 521 49531 8
  110. Is eag the answer to the M-current?
  111. Effects on K+ currents in rat cerebellar granule neurones of a membrane-permeable analogue of the calcium chelator BAPTA
  112. A non-inactivating K+ current sensitive to muscarinic receptor activation in rat cultured cerebellar granule neurons.
  113. Potent block of potassium currents in rat isolated sympathetic neurones by the uncharged form of amitriptyline and related tricyclic compounds
  114. Methods in neurosciences volume 19: Ion channels of excitable cells
  115. Multiple G-protein-coupled pathways inhibit N-type Ca channels of neurons
  116. Modulation of the gating of the transient outward potassium current of rat isolated cerebellar granule neurons by lanthanum
  117. Block of potassium currents in rat isolated sympathetic neurones by tricyclic antidepressants and structurally related compounds
  118. Characterization of muscarinic receptor subtypes inhibiting Ca2+ current and M current in rat sympathetic neurons.
  119. Inhibition of N- and L-type calcium channels by muscarinic receptor activation in rat sympathetic neurons
  120. 5-HT3 receptor channels in dissociated rat superior cervical ganglion neurons.
  121. Conductance and kinetic properties of single nicotinic acetylcholine receptor channels in rat sympathetic neurones.
  122. Intracellular Ca2+ buffers disrupt muscarinic suppression of Ca2+ current and M current in rat sympathetic neurons.
  123. Activation of glutamate receptors and glutamate uptake in identified macroglial cells in rat cerebellar cultures.
  124. Rectification of currents activated by nicotinic acetylcholine receptors in rat sympathetic ganglion neurones.
  125. Chapter 5 Function of nicotinic synapses
  126. Acetylcholine receptor channels and their block by clonidine in cultured bovine chromaffin cells.
  127. Nicotinic acetylcholine receptors of nerve and muscle: Functional aspects
  128. Single-Channel and Whole-Cell Currents Evoked by Acetylcholine in Dissociated Sympathetic Neurons of the Rat
  129. Interactions between the effects of yohimbine, clonidine and [Ca]o on the electrical response of the mouse vas deferens
  130. Ion channels activated by acetylcholine and γ-aminobutyric acid in freshly dissociated sympathetic neurones of the rat
  131. Facilitation at single release sites of a sympathetic neuroeffector junction in the mouse.
  132. α-ADRENORECEPTORS AND FACILITATION AT A SYMPATHETIC NEUROEFFECTOR JUNCTION
  133. Neuronal Potassium Channels